Heterosubstituted pyridine derivatives as PDE4 inhibitors
US6200993A · kind A · utility
13Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2000 |
| Grant date | Mar 13, 2001 |
| Priority date | — |
| Expiry date | Apr 17, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. The invention also encompasses pharmaceutical compositions and methods for treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.